Navigation Links
Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson's Disease
Date:6/18/2013

chronotherapeutic" pharmacokinetic profile is characterized by a slow increase in initial amantadine plasma concentrations, high plasma concentrations during the daytime hours when LID can be troublesome and low plasma concentrations overnight. Adamas is investigating whether the low overnight amantadine plasma concentration may reduce the insomnia, sleep disturbances, and vivid dreams occasionally associated with amantadine. Due to its altered pharmacokinetic profile, ADS-5102 is being investigated in clinical studies at daily dose strengths 1.3 to 2.1 fold greater than the 100 mg twice-daily dose typically used with immediate-release amantadine.

About Levodopa-Induced Dyskinesia

Levodopa (also known as L-dopa) remains the gold standard for the treatment of the debilitating motor symptoms of Parkinson's disease. An unfortunate side effect of prolonged treatment with levodopa is the occurrence of levodopa-induced dyskinesia (LID). LID is characterized by involuntary non-purposeful movements of the head and neck, arms, legs or trunk. With continued levodopa treatment, and as PD progresses, LID can become severely disabling and has been associated with a decrease in the quality of life for Parkinson's patients.1 LID affects approximately 30% of patients taking levodopa2, and is particularly problematic among young-onset Parkinson's disease patients. There are currently no medications approved for the treatment of LID. Reducing LID and improving "ON time" without troublesome dyskinesia are among the greatest patient unmet medical needs in the treatment of advanced Parkinson's disease.3

About Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals is dedicated to improving the lives of those affected by central nervous system (CNS) disorders by optimizing the pharmacokinetic profiles of approved drugs to create novel treatments for use alone and as components of fixed-dose combination products. The Company is cu
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adamas Pharmaceuticals To Report Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia In Parkinsons Disease
2. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
3. Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House
4. Valeant Pharmaceuticals Announces Public Offering Of Common Shares
5. Perrigo Company Acquires Ophthalmic Product Portfolio From Fera Pharmaceuticals, LLC For An Upfront Payment Of $93 Million
6. Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc.
7. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company
8. Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
9. Chronische Nierenerkrankung: Das Risiko des Fortschreitens reduzieren -- Prismic Pharmaceuticals sichert sich exklusive Lizenzrechte
10. Imprimis Pharmaceuticals, Inc. to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
11. Conatus Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... London, UK (PRWEB) , ... September 01, 2015 ... ... of a vacuum that creates negative pressure inside a wound to remove exudates, ... market for treatment devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, ...
(Date:9/1/2015)... ... September 01, 2015 , ... The ... Information Management has been granted continued accreditation based on a successfully completed ... “Achieving and maintaining this accreditation takes the involvement and dedication of each ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... and government entities, announced today that it has hired Scott Sanderson, an experienced ... In this capacity, Sanderson will be responsible for establishing and managing new client ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... Nelson, D.O., has joined its medical management team as an Associate Medical Director. ... all sizes and types in the U.S. and abroad. , Dr. Nelson ...
(Date:9/1/2015)... ... 01, 2015 , ... SC&H Group, a leading audit, tax, and consulting firm, ... of the Best” firm in the U.S., as well as being ranked a Top ... in the U.S., selected exclusively on performance in specific areas of financial and operational ...
Breaking Medicine News(10 mins):Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2
... author,s two-year period of severe depressionBROOKLYN, N.Y., Feb. 27 ... Temple kept a journal, in which the basic underlying ... intolerable, and the result is this fascinating book of ... 100 poems, Temple shares his heartfelt feelings of extremely ...
... Annual Net Sales Driven by Demand for Branded Products- ... from 2007- Provides 2009 Adjusted EPS Guidance Range of ... Pharmaceuticals (Nasdaq: ENDP ) today reported double-digit ... per share for the fourth quarter and full year ...
... Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced ... on Monday, March 9, 2009, at 4:30 p.m. EDT to ... results, and provide an update on recent corporate developments. To ... The live Webcast and replay access of the teleconference will ...
... /PRNewswire-Asia/ -- GE Healthcare, a,leading provider of ... solutions targeted for hospitals and outpatient imaging ... clinical capabilities,the suite provides the robust Web-based ... Dynamic Imaging. , ...
... to the media regarding the PLoS Medicine article published online ... patient who developed "brain tumors" (glioneuronal neoplasms) after undergoing repeated ... 2001. , ... San Diego, California ...
... marketing spend Hallmark Cards today unveiled its plans for a major TV ... A Cure™, campaign. This will be the third year of the ... breast cancer charities by the end of its 2009 Mother,s Day Campaign. ... ...
Cached Medicine News:Health News:Journey into the Dark Recesses of the Subconscious Mind 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 2Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 3Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 4Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 5Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 6Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 7Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 8Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 9Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 10Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 11Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 12Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 13Health News:Endo Pharmaceuticals Reports Fourth Quarter and Full-Year Financial Results 14Health News:GE Healthcare Extends Leading Web-Based Imaging Solutions to Asia 2Health News:GE Healthcare Extends Leading Web-Based Imaging Solutions to Asia 3Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 2Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 3Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 4Health News:Stemedica Medical Team Cautions Patients About Stem Cell Therapy & Comments on PLoS Medicine Article 5Health News:Hallmark Cards Increases Investment In Cards For a Cure™ with Major Advertising and PR Campaign for Mother's Day 2009 2Health News:Hallmark Cards Increases Investment In Cards For a Cure™ with Major Advertising and PR Campaign for Mother's Day 2009 3
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit TAFI Calibrators and Controls...
Plasma Control Level 2 - 1 ml...
Medicine Products: